DoseGear research brief
Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.
DG Peptide Protocols
Well StudiedHealing & RecoveryImmune
Thymosin Beta-4
Tβ4
43-Amino Acid Regenerative Peptide | Tissue Repair & Healing
Research overview
Mechanism of action
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Endogenous 43-amino-acid actin-binding peptide.
What it is researched for
Wound, corneal, and tissue-repair research involving actin sequestration, cell migration, and repair-associated signaling.
Research observation window
Not reported in the reviewed compound-specific evidence. Fragment-product schedules cannot be substituted.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
No sourced lyophilized-vial injectable protocol is listed for this profile.
Safety context
Reported side effects
- Mild injection site reactions
- Local inflammation at injection sites
Contraindications & cautions
- Active chemotherapy treatment
- Severe systemic allergies to peptides
Scientific references
- 01
Phase II Dry Eye Clinical Trial
Scientific citationPhase II Dry Eye Clinical Trial. (2015). - 02
Phase I Human Safety Study: Intravenous Thymosin β4
Scientific citationPhase I Human Safety Study: Intravenous Thymosin β4. (2010). - 03
Cardiac Protection Pilot Study: Thymosin β4 in STEMI Patients
Scientific citationCardiac Protection Pilot Study: Thymosin β4 in STEMI Patients. (2016). - 04
Neurotrophic Keratopathy Compassionate Use Trial
Scientific citationNeurotrophic Keratopathy Compassionate Use Trial. (2010).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.